ERBB2 and breast carcinoma: In addition, also the PARPi niraparib recently showed in a pilot study, a high tumor response (90.5%) on MRI along with high pCR rate (40.0%) in gBRCA-mutant HER2-negative breast cancer patients who received it as monotherapy in the neoadjuvant setting50.